BIOLASE (NASDAQ:BIOL) Price Target Cut to $2.00 by Analysts at Ascendiant Capital Markets

BIOLASE (NASDAQ:BIOL) had its price target reduced by Ascendiant Capital Markets from $3.50 to $2.00 in a research report sent to investors on Tuesday, Benzinga reports. They currently have a buy rating on the medical technology company’s stock.

Other analysts have also recently issued reports about the company. StockNews.com initiated coverage on BIOLASE in a report on Sunday, September 1st. They set a sell rating for the company. Benchmark reissued a speculative buy rating and set a $0.40 price target on shares of BIOLASE in a report on Monday, August 12th. Finally, Maxim Group cut BIOLASE from a strong-buy rating to a hold rating in a report on Friday, May 24th.

BIOLASE Stock Performance

Shares of NASDAQ BIOL opened at $0.06 on Tuesday. BIOLASE has a 12 month low of $0.04 and a 12 month high of $3.85. The stock has a 50 day moving average of $0.07 and a 200-day moving average of $0.12. The company has a market capitalization of $1.87 million, a P/E ratio of 0.00 and a beta of 0.71.

BIOLASE (NASDAQ:BIOL) last issued its earnings results on Thursday, August 8th. The medical technology company reported ($0.08) EPS for the quarter. BIOLASE had a negative return on equity of 1,782.73% and a negative net margin of 41.65%. The business had revenue of $11.56 million for the quarter.

Hedge Funds Weigh In On BIOLASE

A hedge fund recently raised its stake in BIOLASE stock. Virtu Financial LLC lifted its holdings in shares of BIOLASE, Inc. (NASDAQ:BIOL) by 1,068.0% in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 143,537 shares of the medical technology company’s stock after buying an additional 131,248 shares during the period. Virtu Financial LLC owned about 0.43% of BIOLASE worth $27,000 as of its most recent filing with the SEC. 8.79% of the stock is currently owned by institutional investors and hedge funds.

About BIOLASE

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.